Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.68 USD
-0.12 (-3.16%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.67 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 341 - 360 ( 432 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q16: ProTmune and FATE-NK100 Promise a Lively 2017; Lowering PT to $6 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q FY16, Fate Looks Compelling Ahead of Data-Rich Year, Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Conference 2017 Takeaways and 4Q16 Results; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Adds to iPSC Technology, Expanded Platform Promising Immuno-oncology Play, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH Presentations Showcase Versatility of Technology Platform
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional ASH Updates for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ProTmune Trial Protocol Amended; Impressive Preclinical ASH Lineup
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q16: Rejigging the PROTECT Study May Have Long-term Payoff for ProTmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ProTmune Study Protocol Amended to Support Potential for Accelerated Approval, Trimming Price Target to $7 (from $8)
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of Fate Therapeutics, Inc. with a Buy rating and a target price of $8
Provider: Roth Capital Partners, Inc.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The A to Z of HSCT: Investor?s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.